Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study

Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study

Background/Aims The efficacy and safety of vedolizumab in moderate-to-severely active Crohn’s disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy and safety of vedolizumab in the subgroup of patients from Asian countries...

Full description

Bibliographic Details
Main Authors: Rupa Banerjee, Sai Wei Chuah, Ida Normiha Hilmi, Deng-Chyang Wu, Suk-Kyun Yang, Dirk Demuth, Dirk Lindner, Shashi Adsul
Format: Article
Language:English
Published: Korean Association for the Study of Intestinal Diseases 2021-01-01
Series:Intestinal Research
Subjects:
vedolizumab
crohn disease
asia
remission
maintenance
Online Access:http://www.irjournal.org/upload/pdf/ir-2019-09160.pdf

Internet

http://www.irjournal.org/upload/pdf/ir-2019-09160.pdf

Similar Items